comparemela.com

Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday. Other equities research analysts also recently issued research reports about the company. Bank of America dropped their target price on Ascendis Pharma A/S from $132.00 […]

Related Keywords

United States ,Denmark ,Hellerup ,Hovedstaden ,America ,Jan Moller Mikkelsen ,Harald Rau ,Ascendis Pharma ,Dirk Vetter ,Credit Suisse Group ,Envestnet Asset Management Inc ,Ascendis Pharmaas Company Profile ,York Mellon Corp ,Citigroup ,Blackrock Inc ,Affinity Asset Advisors ,Morgan Stanley ,Rice Hall James Associates ,Get Rating ,Suisse Group ,Asset Management ,Hall James ,New York Mellon Corp ,Ascendis Pharmaa S ,Nasdaq Asnd ,Wasnd ,Medical ,Upgrade ,Stocknews Com ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.